Empirical Study on the Transparency of Security Risk Information in Chinese Listed Pharmaceutical Enterprises Based on the ANP-DS Method

被引:0
作者
Wang, Jining [1 ]
Guo, Chong [1 ]
Chen, Tingqiang [1 ,2 ]
机构
[1] Nanjing Tech Univ, Sch Econ & Management, Nanjing 211816, Peoples R China
[2] Nanjing Tech Univ, Res Ctr Big Data Decis Making & Social Performanc, Nanjing 211816, Peoples R China
基金
国家教育部科学基金资助; 中国国家自然科学基金;
关键词
SAFETY INFORMATION; PUBLIC-HEALTH; COMMUNICATION; DISCLOSURE; SELECTION; COMPANY; SYSTEMS; FIRMS;
D O I
10.1155/2020/4109354
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Frequent outbreaks of drug safety incidents pose a massive threat to public health and safety, while the transparency of security risk information in medical enterprises is not optimistic. Therefore, this study uses the analytic network process (Dempster-Shafer method) to construct a transparent comprehensive evaluation model for security risk information in listed pharmaceutical enterprises from the perspective of government supervision and listed pharmaceutical enterprises. On the basis of 59,305 data obtained by 303 enterprises listed in the Chinese biomedical sector, this research conducted an empirical study on the transparency of safety risk information in Chinese listed pharmaceutical enterprises. The current study found that the transparency of security risk information in Chinese listed pharmaceutical enterprises is generally between "general" and "relatively good" and tends to be "relatively good." However, administrative punishment information, adverse drug reaction reporting systems, and production processes need continuous improvement.
引用
收藏
页数:15
相关论文
共 66 条
[41]  
Nishizawa K, 2010, RAIRO-OPER RES, V34, P313
[42]   Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study [J].
Norris, Susan L. ;
Holmer, Haley K. ;
Ogden, Lauren A. ;
Burda, Brittany U. ;
Fu, Rongwei .
BMC MEDICAL ETHICS, 2012, 13 :24
[43]   A 1year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? [J].
Pea, Federico ;
Cojutti, Piergiorgio ;
Dose, Lucia ;
Baraldo, Massimo .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (02) :341-348
[44]  
Qi M., 2012, Chinese Law Government, V45, P3, DOI DOI 10.2753/CLG0009-4609450100
[45]   Public funding and private investment for R&D: a survey in China's pharmaceutical industry [J].
Qiu, Lan ;
Chen, Zi-Ya ;
Lu, Deng-Yu ;
Hu, Hao ;
Wang, Yi-Tao .
HEALTH RESEARCH POLICY AND SYSTEMS, 2014, 12
[46]   Cultural impact on Chinese corporate disclosure - a corporate governance perspective [J].
Qu, Wen ;
Leung, Philomena .
MANAGERIAL AUDITING JOURNAL, 2006, 21 (03) :241-+
[47]  
Saaty T. L., 1996, ANAL NETWORK PROCESS
[48]   Reliability assessment for multi-state systems under uncertainties based on the DempsterShafer theory [J].
Sallak, Mohamed ;
Schoen, Walter ;
Aguirre, Felipe .
IIE TRANSACTIONS, 2013, 45 (09) :995-1007
[49]  
Sayer J. A, 2002, CONSERV ECOL, V5, P213
[50]   Corporate information transparency The synthesis of internal and external information streams [J].
Simon, Carol .
JOURNAL OF MANAGEMENT DEVELOPMENT, 2006, 25 (10) :1029-1031